| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S1474-4422(16)30230-7 |
| P698 | PubMed publication ID | 27751556 |
| P50 | author | Michael A Schwarzschild | Q66922801 |
| Alberto Ascherio | Q67175546 | ||
| P2860 | cites work | Rotenone, paraquat, and Parkinson's disease | Q22241595 |
| Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis | Q22242250 | ||
| How common are the "common" neurologic disorders? | Q22306182 | ||
| Plantation work and risk of Parkinson disease in a population-based longitudinal study | Q23909315 | ||
| Dietary fat intake and risk for Parkinson's disease | Q23914947 | ||
| Persistent organochlorine pesticides in serum and risk of Parkinson disease | Q23917333 | ||
| Use of ibuprofen and risk of Parkinson disease | Q24594751 | ||
| Neuroprotection by caffeine: time course and role of its metabolites in the MPTP model of Parkinson's disease | Q24604052 | ||
| Solvent exposures and Parkinson disease risk in twins | Q24613285 | ||
| Coffee, caffeine, and risk of depression among women | Q24622276 | ||
| The genetics of hyperuricaemia and gout | Q24629964 | ||
| Neuroprotective and anti-inflammatory properties of a coffee component in the MPTP model of Parkinson's disease | Q24630237 | ||
| Consumption of dairy products and risk of Parkinson's disease | Q24653226 | ||
| Protective effects of NSAIDs on the development of Alzheimer disease | Q24656148 | ||
| Simvastatin is associated with a reduced incidence of dementia and Parkinson's disease | Q24673755 | ||
| Caffeine in Parkinson disease: better for cruise control than snooze patrol? | Q84706649 | ||
| Dietary and lifestyle variables in relation to incidence of Parkinson's disease in Greece | Q86048543 | ||
| Age, statin use, and the risk for incident Parkinson disease-reply | Q86930969 | ||
| Measles infection and Parkinson's disease | Q93642209 | ||
| The prediagnostic phase of Parkinson's disease | Q26768732 | ||
| Genetics of Parkinson's disease | Q26827825 | ||
| Parkinson's disease, insulin resistance and novel agents of neuroprotection | Q26853311 | ||
| Manganism in the 21st century: the Hanninen lecture | Q27015750 | ||
| Nonsteroidal antiinflammatory drug use and the risk for Parkinson's disease | Q28192834 | ||
| Nonsteroidal anti-inflammatory drugs and risk of Parkinson's disease | Q28195845 | ||
| Nonsteroidal anti-inflammatory drugs and the incidence of Parkinson disease | Q28196448 | ||
| Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease | Q28199468 | ||
| Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease | Q28221401 | ||
| Gout and the risk of Parkinson's disease: a cohort study | Q28299347 | ||
| Midlife milk consumption and substantia nigra neuron density at death | Q28386999 | ||
| CNS infections, sepsis and risk of Parkinson's disease | Q28387937 | ||
| Parkinson's disease research in a prospective cohort in China | Q28389811 | ||
| Neuroprotective effects of urate are mediated by augmenting astrocytic glutathione synthesis and release | Q28393646 | ||
| Genetic modification of the association of paraquat and Parkinson's disease | Q28394396 | ||
| Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes | Q29614548 | ||
| Epidemiology of Parkinson's disease | Q29614901 | ||
| Neuroinflammation in Parkinson's disease: a target for neuroprotection? | Q29616300 | ||
| Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators | Q29617353 | ||
| Midlife adiposity and the future risk of Parkinson's disease | Q30310111 | ||
| Serum urate as a predictor of clinical and radiographic progression in Parkinson disease | Q30440692 | ||
| The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service | Q33183516 | ||
| Alcohol use disorders and risk of Parkinson's disease: findings from a Swedish national cohort study 1972-2008 | Q33643115 | ||
| The relationship between uric acid levels and Huntington's disease progression | Q33699054 | ||
| Smoking duration, intensity, and risk of Parkinson disease | Q33720760 | ||
| Antihypertensive agents and risk of Parkinson's disease: a nationwide cohort study | Q33727268 | ||
| Female reproductive factors, menopausal hormone use, and Parkinson's disease | Q33756791 | ||
| Caffeine protects against combined paraquat and maneb-induced dopaminergic neuron degeneration | Q33828847 | ||
| Geographic and ethnic variation in Parkinson disease: a population-based study of US Medicare beneficiaries. | Q33832927 | ||
| Urate as a predictor of the rate of clinical decline in Parkinson disease | Q34019732 | ||
| Statin use and Parkinson's disease in Denmark | Q34020626 | ||
| Physical activities and future risk of Parkinson disease | Q34054934 | ||
| Vigorous-intensity leisure-time physical activity and risk of major chronic disease in men. | Q36243539 | ||
| Prospective study of dietary pattern and risk of Parkinson disease | Q36426202 | ||
| Temporal relationship between cigarette smoking and risk of Parkinson disease | Q36426206 | ||
| Smoking and risk of skin cancer: a prospective analysis and a meta-analysis | Q36504747 | ||
| Disrupted and transgenic urate oxidase alter urate and dopaminergic neurodegeneration | Q36512151 | ||
| Metabolic markers or conditions preceding Parkinson's disease: a case-control study | Q36516892 | ||
| Is the MC1R variant p.R160W associated with Parkinson's? | Q36535790 | ||
| Alcohol and risk of Parkinson's disease in a large, prospective cohort of men and women | Q36543263 | ||
| Caffeine and risk of Parkinson's disease in a large cohort of men and women | Q36560201 | ||
| Prospective study of plasma urate and risk of Parkinson disease in men and women | Q36580376 | ||
| Parkinson's disease in Africa: A systematic review of epidemiologic and genetic studies | Q36624661 | ||
| The genetics of Parkinson's disease: progress and therapeutic implications | Q36626825 | ||
| Incidence of Parkinson's disease in Singapore | Q36630480 | ||
| Diet, urate, and Parkinson's disease risk in men. | Q36632177 | ||
| Promotion of physical activity and fitness in sedentary patients with Parkinson's disease: randomised controlled trial | Q36649039 | ||
| Telomere length and risk of Parkinson's disease | Q36663122 | ||
| Recreational physical activity and risk of Parkinson's disease | Q36663157 | ||
| Plasma urate and risk of Parkinson's disease | Q36667290 | ||
| Hypertension, hypercholesterolemia, diabetes, and risk of Parkinson disease | Q36667311 | ||
| Short communication: genetic variations of SLC2A9 in relation to Parkinson's disease | Q36686805 | ||
| Personality traits and the risk for Parkinson disease: a prospective study | Q36762795 | ||
| Obesity, diabetes, and risk of Parkinson's disease | Q36769272 | ||
| Nicotine neuroprotection against nigrostriatal damage: importance of the animal model | Q36782419 | ||
| Gout and the risk of Parkinson's disease in Denmark | Q36847424 | ||
| Prospective cohort study of type 2 diabetes and the risk of Parkinson's disease | Q36906241 | ||
| Calcium, ageing, and neuronal vulnerability in Parkinson's disease | Q36947731 | ||
| Risk of Parkinson's disease after hospital contact for head injury: population based case-control study | Q37016781 | ||
| Differential effects of black versus green tea on risk of Parkinson's disease in the Singapore Chinese Health Study | Q37044339 | ||
| Genetic determinants of hair color and Parkinson's disease risk | Q37091302 | ||
| Nonsteroidal anti-inflammatory drugs in experimental parkinsonian models and Parkinson's disease | Q37185098 | ||
| Dietary iron intake and risk of Parkinson's disease | Q37305887 | ||
| Plasma urate and Parkinson's disease in the Atherosclerosis Risk in Communities (ARIC) study | Q37306126 | ||
| Plasma urate and progression of mild cognitive impairment | Q37349919 | ||
| Reproductive factors, exogenous estrogen use, and risk of Parkinson's disease | Q37362137 | ||
| Exposure to estrogen and women's risk for Parkinson's disease: a prospective cohort study in Denmark. | Q50558296 | ||
| Smoking and Parkinson's disease in twins. | Q52937589 | ||
| Type 2 diabetes and the risk of Parkinson's disease. | Q53016612 | ||
| Metformin-inclusive sulfonylurea therapy reduces the risk of Parkinson's disease occurring with Type 2 diabetes in a Taiwanese population cohort. | Q53098272 | ||
| A long-term study of istradefylline safety and efficacy in patients with Parkinson disease. | Q53579832 | ||
| Reduced incidence of Parkinson's disease after dipeptidyl peptidase-4 inhibitors-A nationwide case-control study. | Q53708979 | ||
| Parkinson's disease | Q54072241 | ||
| Use of antihypertensives and the risk of Parkinson disease | Q56568485 | ||
| Head injury and Parkinson's disease: A population-based study | Q57127081 | ||
| Blood donations, iron stores, and risk of Parkinson's disease | Q57127544 | ||
| Variation in the Uric Acid Transporter Gene SLC2A9 and Its Association with AAO of Parkinson’s Disease | Q57273759 | ||
| Reduced risk of Parkinson’s disease associated with lower body mass index and heavy leisure-time physical activity | Q57303249 | ||
| Prospective study of coffee consumption and risk of Parkinson's disease | Q57303276 | ||
| Cigarette smoking and the incidence of Parkinson's disease in two prospective studies | Q57750580 | ||
| Serum cholesterol, use of lipid-lowering drugs, and risk of Parkinson disease | Q57781918 | ||
| Serum Cholesterol Levels and the Risk of Parkinson's Disease | Q57781973 | ||
| Serum uric acid levels and the risk of Parkinson disease | Q57782006 | ||
| NSAID use and risk of Parkinson disease: a population-based case-control study | Q57950713 | ||
| Malignant Melanoma and Other Types of Cancer Preceding Parkinson Disease | Q58006630 | ||
| Gout and risk of Parkinson disease: A prospective study | Q59305366 | ||
| Statin use and the risk of Parkinson disease: a nested case control study | Q59417487 | ||
| Body mass index and the risk of Parkinson disease | Q59542870 | ||
| Influence of strict, intermediate, and broad diagnostic criteria on the age- and sex-specific incidence of Parkinson's disease | Q64768764 | ||
| The frequency of idiopathic Parkinson's disease by age, ethnic group, and sex in northern Manhattan, 1988-1993 | Q71775128 | ||
| Association between Parkinson's disease and exposure to pesticides in southwestern France | Q73765632 | ||
| Malignant melanoma in early Parkinson's disease: the DATATOP trial | Q79992441 | ||
| Immunologic diseases, anti-inflammatory drugs, and Parkinson disease: a case-control study | Q80071482 | ||
| Smokeless tobacco use and the risk of Parkinson's disease mortality | Q80353817 | ||
| Body mass index and risk of Parkinson's disease: a prospective cohort study | Q80819120 | ||
| Coffee and tea consumption and the risk of Parkinson's disease | Q80827650 | ||
| Subsequent risks of Parkinson disease in patients with autoimmune and related disorders: a nationwide epidemiological study from Sweden | Q83149926 | ||
| Caffeine in Parkinson's disease: comment on its importance and the dose proposal | Q83879510 | ||
| Statins, plasma cholesterol, and risk of Parkinson's disease: a prospective study | Q35328089 | ||
| Uric acid levels predict survival in men with amyotrophic lateral sclerosis | Q35638492 | ||
| Traumatic brain injury in later life increases risk for Parkinson disease | Q35661022 | ||
| No association between Parkinson disease alleles and the risk of melanoma | Q35661342 | ||
| Body Mass Index and Risk of Parkinson's Disease: A Dose-Response Meta-Analysis of Prospective Studies | Q35677372 | ||
| Calcium channel blockers and beta-blockers in relation to Parkinson's disease | Q35845076 | ||
| Habitual intake of dietary flavonoids and risk of Parkinson disease | Q35872348 | ||
| Risk of Parkinson disease onset in patients with diabetes: a 9-year population-based cohort study with age and sex stratifications. | Q35898211 | ||
| Treatment for Helicobacter pylori infection and risk of Parkinson's disease in Denmark | Q35899185 | ||
| Caffeine intake, smoking, and risk of Parkinson disease in men and women | Q36019163 | ||
| Gout and the risk of Alzheimer's disease: a population-based, BMI-matched cohort study | Q36029745 | ||
| Lipid-lowering drugs and mitochondrial function: effects of HMG-CoA reductase inhibitors on serum ubiquinone and blood lactate/pyruvate ratio | Q36093796 | ||
| Prognostic Role of Serum Levels of Uric Acid in Amyotrophic Lateral Sclerosis. | Q36130114 | ||
| Relationship between impulsive sensation seeking traits, smoking, alcohol and caffeine intake, and Parkinson's disease | Q36142954 | ||
| Caffeine Intake, Coffee Consumption, and Risk of Cutaneous Malignant Melanoma | Q36143436 | ||
| Caffeine for treatment of Parkinson disease: a randomized controlled trial | Q36149963 | ||
| Decaffeinated coffee and nicotine-free tobacco provide neuroprotection in Drosophila models of Parkinson's disease through an NRF2-dependent mechanism | Q34111402 | ||
| Calcium channel blocker use and risk of Parkinson's disease | Q34126927 | ||
| Prenatal and early life factors and risk of Parkinson's disease | Q34133288 | ||
| Plasma urate and Parkinson's disease in women | Q34179611 | ||
| Incidence of Parkinson's disease: variation by age, gender, and race/ethnicity | Q34201593 | ||
| Purine-rich foods, dairy and protein intake, and the risk of gout in men. | Q34304862 | ||
| Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease | Q34358956 | ||
| Particulate matter and risk of Parkinson disease in a large prospective study of women | Q34363409 | ||
| Parkinson disease and smoking revisited: ease of quitting is an early sign of the disease | Q34386576 | ||
| Coffee consumption and total mortality: a meta-analysis of twenty prospective cohort studies | Q34388147 | ||
| Effect of ethanol on metabolism of purine bases (hypoxanthine, xanthine, and uric acid). | Q34423829 | ||
| Dose-related decrease of serum coenzyme Q10 during treatment with HMG-CoA reductase inhibitors | Q34436371 | ||
| Use of non-steroidal anti-inflammatory drugs and risk of Parkinson's disease: nested case-control study | Q34505182 | ||
| Association of coffee and caffeine intake with the risk of Parkinson disease | Q34508881 | ||
| Prospective study of caffeine consumption and risk of Parkinson's disease in men and women. | Q34516364 | ||
| Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline | Q34528059 | ||
| Pesticide exposure and risk for Parkinson's disease | Q34542115 | ||
| Dietary folate, vitamin B12, and vitamin B6 and the risk of Parkinson disease | Q34569327 | ||
| Mendelian randomization of serum urate and parkinson disease progression | Q34576895 | ||
| Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial | Q34658560 | ||
| Increased risk of parkinsonism in women who underwent oophorectomy before menopause. | Q34673129 | ||
| Pathogenesis of Parkinson disease--the gut-brain axis and environmental factors | Q34674177 | ||
| Diabetes and risk of Parkinson's disease | Q34718429 | ||
| Smoking and Parkinson's disease: using parental smoking as a proxy to explore causality | Q34917908 | ||
| Serum vitamin D and the risk of Parkinson disease | Q34962536 | ||
| Methamphetamine/amphetamine abuse and risk of Parkinson's disease in Utah: a population-based assessment | Q34973698 | ||
| Coffee drinking and cutaneous melanoma risk in the NIH-AARP diet and health study | Q35029323 | ||
| Diabetes and the risk of developing Parkinson's disease in Denmark. | Q35043736 | ||
| Meta-analysis of the relationship between Parkinson disease and melanoma | Q35049770 | ||
| The risk of Parkinson disease associated with urate in a community-based cohort of older adults. | Q35071745 | ||
| Neuroprotective agents for clinical trials in Parkinson's disease: a systematic assessment | Q35111748 | ||
| Physical activity and risk of Parkinson's disease: a prospective cohort study | Q35148041 | ||
| Malignant melanoma in early-treated Parkinson's disease: the NET-PD trial | Q35221729 | ||
| Risk of incident diabetes in patients with gout: a cohort study. | Q35256172 | ||
| Dietary intakes of fat and risk of Parkinson's disease | Q44460127 | ||
| Methamphetamine-induced deficits of brain monoaminergic neuronal markers: distal axotomy or neuronal plasticity | Q44654013 | ||
| Obesity and the risk of Parkinson's disease | Q44788559 | ||
| Low LDL cholesterol and increased risk of Parkinson's disease: prospective results from Honolulu-Asia Aging Study | Q44937268 | ||
| Folate intake and risk of Parkinson's disease | Q45001491 | ||
| Risk and protective factors for Parkinson's disease: a study in Swedish twins | Q45134630 | ||
| Coffee consumption, gender, and Parkinson's disease mortality in the cancer prevention study II cohort: the modifying effects of estrogen | Q45136825 | ||
| Physical activity and the risk of Parkinson disease | Q45296127 | ||
| Serum uric acid and cognitive function and dementia | Q45803489 | ||
| Physical activity and risk of Parkinson's disease in the Swedish National March Cohort. | Q45973045 | ||
| Genetic variability related to serum uric acid concentration and risk of Parkinson's disease. | Q45980386 | ||
| Use of calcium channel blockers and Parkinson's disease | Q46063768 | ||
| Variations in gender ratios support the connection between smoking and Parkinson's disease | Q46567569 | ||
| Dietary fatty acids and the risk of Parkinson disease: the Rotterdam study | Q46572879 | ||
| The effect of Simvastatin on the plasma antioxidant concentrations in patients with hypercholesterolaemia | Q46599895 | ||
| Use of statins and the risk of Parkinson's disease: a retrospective case-control study in the UK. | Q46636768 | ||
| Total cholesterol and the risk of Parkinson disease | Q46653844 | ||
| Estrogen prevents neuroprotection by caffeine in the mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. | Q46890609 | ||
| Common anti-inflammatory drugs are potentially therapeutic for Parkinson's disease? | Q48122306 | ||
| Neuroprotection by urate on 6-OHDA-lesioned rat model of Parkinson's disease: linking to Akt/GSK3β signaling pathway | Q48323370 | ||
| Cancer incidence in a trial of an antiapoptotic agent for Parkinson's disease | Q48532454 | ||
| Observations on serum uric acid levels and the risk of idiopathic Parkinson's disease | Q48937328 | ||
| Family history of melanoma and Parkinson disease risk | Q37393477 | ||
| Parkinson's disease and cancer: A register-based family study | Q37396182 | ||
| Unrecognized vitamin D3 deficiency is common in Parkinson disease: Harvard Biomarker Study | Q37463473 | ||
| Socioeconomic status in relation to Parkinson's disease risk and mortality: A population-based prospective study | Q37605657 | ||
| Telomere length and Parkinson's disease in men: a nested case-control study | Q37619738 | ||
| Parkinson's disease and cancer risk: a systematic review and meta-analysis | Q37669823 | ||
| When does Parkinson disease start? | Q37772029 | ||
| Epidemiology and etiology of Parkinson's disease: a review of the evidence | Q37882546 | ||
| Shared dysregulated pathways lead to Parkinson's disease and diabetes | Q38078667 | ||
| Exercise: is it a neuroprotective and if so, how does it work? | Q38164870 | ||
| Systematic review of the risk of Parkinson's disease after mild traumatic brain injury: results of the International Collaboration on Mild Traumatic Brain Injury Prognosis | Q38192206 | ||
| Time trends in incidence of Parkinson's disease diagnosis in UK primary care | Q38428462 | ||
| A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit | Q38433785 | ||
| Exercise-induced neuroplasticity in human Parkinson's disease: What is the evidence telling us? | Q38600123 | ||
| Time Trends in the Incidence of Parkinson Disease | Q38870766 | ||
| Prediagnostic presentations of Parkinson's disease in primary care: a case-control study | Q39092409 | ||
| Statin therapy prevents the onset of Parkinson disease in patients with diabetes. | Q39546196 | ||
| Statin use and risk of Parkinson's disease: a meta-analysis of observational studies. | Q39582097 | ||
| Trends in the Incidence of Parkinson Disease in the General Population: The Rotterdam Study | Q39759171 | ||
| Exploring the Association Between Rosacea and Parkinson Disease: A Danish Nationwide Cohort Study | Q39902071 | ||
| Reduction of nuclear peroxisome proliferator-activated receptor gamma expression in methamphetamine-induced neurotoxicity and neuroprotective effects of ibuprofen | Q40406674 | ||
| Consumption of milk and calcium in midlife and the future risk of Parkinson disease | Q40436399 | ||
| Cigarette smoking and protection from Parkinson's disease: false association or etiologic clue? | Q40546558 | ||
| Neuroprotective effects of prior limb use in 6-hydroxydopamine-treated rats: possible role of GDNF. | Q40658454 | ||
| Prospective study on the components of metabolic syndrome and the incidence of Parkinson's disease | Q41528975 | ||
| Hepatitis C virus infection: a risk factor for Parkinson's disease | Q41530271 | ||
| Tozadenant (SYN115) in patients with Parkinson's disease who have motor fluctuations on levodopa: a phase 2b, double-blind, randomised trial | Q42704885 | ||
| Heterogeneity in male to female risk for Parkinson's disease | Q42765838 | ||
| Incidence of Parkinson's disease among hospital patients with methamphetamine‐use disorders | Q42926652 | ||
| Dairy foods intake and risk of Parkinson's disease: a dose-response meta-analysis of prospective cohort studies | Q43547318 | ||
| Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease | Q43624453 | ||
| A cohort study on diet and the risk of Parkinson's disease: the role of food groups and diet quality | Q43647112 | ||
| Green tea polyphenol (-)-epigallocatechin-3-gallate prevents N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurodegeneration | Q43735211 | ||
| Protection of midbrain dopaminergic neurons by the end-product of purine metabolism uric acid: potentiation by low-level depolarization. | Q43805282 | ||
| Dietary folate deficiency and elevated homocysteine levels endanger dopaminergic neurons in models of Parkinson's disease | Q43858155 | ||
| Alcohol intake and risk of Parkinson's disease: a meta-analysis of observational studies | Q43888293 | ||
| Parkinsonism in a population of northern Tanzania: a community-based door-to-door study in combination with a prospective hospital-based evaluation | Q43942444 | ||
| The prevalence of Parkinson's disease in rural Tanzania | Q43944347 | ||
| Loss of urate oxidase activity in hominoids and its evolutionary implications | Q43964677 | ||
| NSAIDS for prevention? Protecting the brain while killing pain? | Q44113054 | ||
| Intakes of vitamins E and C, carotenoids, vitamin supplements, and PD risk. | Q44187776 | ||
| Diet and Parkinson's disease: a potential role of dairy products in men. | Q44226816 | ||
| Risk tables for parkinsonism and Parkinson's disease. | Q44309519 | ||
| Caffeine, postmenopausal estrogen, and risk of Parkinson's disease | Q44357392 | ||
| P433 | issue | 12 | |
| P921 | main subject | Parkinson's disease | Q11085 |
| P304 | page(s) | 1257-1272 | |
| P577 | publication date | 2016-10-11 | |
| P1433 | published in | Lancet Neurology | Q15755067 |
| P1476 | title | The epidemiology of Parkinson's disease: risk factors and prevention | |
| P478 | volume | 15 |
| Q92479201 | A dual druggable genome-wide siRNA and compound library screening approach identifies modulators of parkin recruitment to mitochondria |
| Q64764591 | A metabolic profile of polyamines in parkinson disease: A promising biomarker |
| Q58803163 | A new hypothesis for Parkinson's disease pathogenesis: GTPase-p38 MAPK signaling and autophagy as convergence points of etiology and genomics |
| Q53684476 | A53T-α-synuclein overexpression in murine locus coeruleus induces Parkinson's disease-like pathology in neurons and glia. |
| Q47095276 | Adenosine A1-A2A Receptor Heteromer as a Possible Target for Early-Onset Parkinson's Disease |
| Q64764558 | Alpha-synuclein at the nexus of genes and environment: the impact of environmental enrichment and stress on brain health and disease |
| Q55003224 | Amyotrophic Lateral Sclerosis (ALS) and Adenosine Receptors. |
| Q53070472 | An Enriched Environment Ameliorates Oxidative Stress and Olfactory Dysfunction in Parkinson's Disease with α-Synucleinopathy. |
| Q90633100 | An Integrated Network Analysis of mRNA and Gene Expression Profiles in Parkinson's Disease |
| Q90118142 | Anemia and the risk of Parkinson's disease in Korean older adults: A nationwide population-based study |
| Q93073764 | Antibiotic-induced microbiome depletion protects against MPTP-induced dopaminergic neurotoxicity in the brain |
| Q64279756 | Aquaporin-4 deficiency reduces TGF-β1 in mouse midbrains and exacerbates pathology in experimental Parkinson's disease |
| Q88325325 | Assessment of serum uric acid as risk factor for tauopathies |
| Q90638319 | Association Between Parkinson's Disease and Melanoma: Putting the Pieces Together |
| Q59335785 | Association Between Serum Vitamin D Levels and Parkinson's Disease: A Systematic Review and Meta-Analysis |
| Q60956572 | Association of , , and With Parkinson's Disease in Southern Chinese |
| Q64764549 | Association of Antiviral Therapy With Risk of Parkinson Disease in Patients With Chronic Hepatitis C Virus Infection |
| Q51129501 | Association of IGF1 gene polymorphism with Parkinson's disease in a Han Chinese population. |
| Q64785297 | Association of Levels of Physical Activity With Risk of Parkinson Disease: A Systematic Review and Meta-analysis |
| Q91405170 | Behavioural and dopaminergic changes in double mutated human A30P*A53T alpha-synuclein transgenic mouse model of Parkinson´s disease |
| Q47137783 | Biological and Clinical Implications of Comorbidities in Parkinson's Disease |
| Q42654200 | Biomarkers and Stimulation Algorithms for Adaptive Brain Stimulation |
| Q64782430 | Brain cholesterol metabolism and Parkinson's disease |
| Q64105254 | C-Reactive Protein and Risk of Parkinson's Disease: A Systematic Review and Meta-Analysis |
| Q58765503 | CRISPR/Cas9-Mediated Generation of Guangxi Bama Minipigs Harboring Three Mutations in α-Synuclein Causing Parkinson's Disease |
| Q64110528 | Cardiovascular risk factors and Parkinson's disease in 500,000 Chinese adults |
| Q100512350 | Characterization of a Cul9-Parkin double knockout mouse model for Parkinson's disease |
| Q97527835 | Characterization of a pathogenic variant in GBA for Parkinson's disease with mild cognitive impairment patients |
| Q97420297 | Chasing Protection in Parkinson's Disease: Does Exercise Reduce Risk and Progression? |
| Q47923287 | Cognitive and Neuropsychiatric Features in Parkinson's and Lewy Body Dementias |
| Q88419158 | Combating Neurodegenerative Diseases with the Plant Alkaloid Berberine: Molecular Mechanisms and Therapeutic Potential |
| Q64110531 | Comparison of Efficacy of Deep Brain Stimulation of Different Targets in Parkinson's Disease: A Network Meta-Analysis |
| Q90174296 | Comparison of long-term use of prolonged-release ropinirole and immediate-release dopamine agonists in an observational study in patients with Parkinson's disease |
| Q49907865 | Cyclooxygenase 2 is upregulated in the gastrointestinal tract in Parkinson's disease |
| Q92363959 | DNA methylation changes associated with Parkinson's disease progression: outcomes from the first longitudinal genome-wide methylation analysis in blood |
| Q57173290 | Deep brain stimulation for the treatment of disorders of consciousness and cognition in traumatic brain injury patients: a review |
| Q49626403 | Dietary antioxidants and Parkinson's disease |
| Q64764742 | Dietary intake of glucoraphanin prevents the reduction of dopamine transporter in the mouse striatum after repeated administration of MPTP |
| Q61449551 | Distinct Stress Response and Altered Striatal Transcriptome in Alpha-Synuclein Overexpressing Mice |
| Q45071393 | Dopamine Modulates Serotonin Innervation in the Drosophila Brain |
| Q38657775 | Dopamine Transporter Neuroimaging as an Enrichment Biomarker in Early Parkinson's Disease Clinical Trials: A Disease Progression Modeling Analysis. |
| Q98386568 | Downregulation of ATP13A2 in midbrain dopaminergic neurons is related to defective autophagy in a mouse model of Parkinson's disease |
| Q92355102 | Effect of the micro-immunotherapy medicine 2LPARK® on rat primary dopaminergic neurons after 6-OHDA injury: oxidative stress and survival evaluation in an in vitro model of Parkinson's disease |
| Q99711416 | Effectiveness of Acupuncture in the Treatment of Parkinson's Disease: An Overview of Systematic Reviews |
| Q64100254 | Effectiveness of Integrative Therapy for Parkinson's Disease Management |
| Q64282808 | Effects of α-Synuclein Monomers Administration in the Gigantocellular Reticular Nucleus on Neurotransmission in Mouse Model |
| Q64250616 | Electrical Property of Graphene and Its Application to Electrochemical Biosensing |
| Q90248277 | Electromyography Biomarkers for Quantifying the Intraoperative Efficacy of Deep Brain Stimulation in Parkinson's Patients With Resting Tremor |
| Q90589159 | Emerging novel approaches to drug research and diagnosis of Parkinson's disease |
| Q91828425 | Empathy In Neurodegenerative Diseases: A Systematic Review |
| Q54943751 | Environment-dependent striatal gene expression in the BACHD rat model for Huntington disease. |
| Q54942969 | Environmental Enrichment Prevents Transcriptional Disturbances Induced by Alpha-Synuclein Overexpression |
| Q40294127 | Epidemiology and causes of Parkinson's disease |
| Q58584617 | Epidemiology of Parkinson's Disease-East Versus West |
| Q55257291 | Evaluation of RNA Blood Biomarkers in the Parkinson's Disease Biomarkers Program. |
| Q92165496 | Exposure to Pesticides and Welding Hastens the Age-at-Onset of Parkinson's Disease |
| Q58614545 | FOXRED1 silencing in mice: a possible animal model for Leigh syndrome |
| Q56243511 | Factors associated with dream enacting behaviors among US farmers |
| Q94562623 | Four main therapeutic keys for Parkinson's disease: A mini review |
| Q90321601 | Functional and Neuroprotective Role of Striatal Adenosine A2A Receptor Heterotetramers |
| Q89850494 | Functional nanoarrays for investigating stem cell fate and function |
| Q98195633 | GCH1 variants contribute to the risk and earlier age-at-onset of Parkinson's disease: a two-cohort case-control study |
| Q92857321 | Gangliosides: Treatment Avenues in Neurodegenerative Disease |
| Q90442301 | Genome aging: somatic mutation in the brain links age-related decline with disease and nominates pathogenic mechanisms |
| Q49698299 | Glut9-mediated Urate Uptake Is Responsible for Its Protective Effects on Dopaminergic Neurons in Parkinson's Disease Models |
| Q90296525 | HIF-1α/microRNA-128-3p axis protects hippocampal neurons from apoptosis via the Axin1-mediated Wnt/β-catenin signaling pathway in Parkinson's disease models |
| Q38658595 | Head trauma and Parkinson's disease: results from an Italian case-control study |
| Q92155440 | Health Benefits of Endurance Training: Implications of the Brain-Derived Neurotrophic Factor-A Systematic Review |
| Q92809504 | Health Care Costs and Savings Associated with Increased Dairy Consumption among Adults in the United States |
| Q48171209 | How does parkinson's disease begin? Perspectives on neuroanatomical pathways, prions, and histology |
| Q47698588 | How important is tryptophan in human health? |
| Q90062620 | Inflammaging and Oxidative Stress in Human Diseases: From Molecular Mechanisms to Novel Treatments |
| Q64814708 | Information processing deficit in older adults with HIV infection: A comparison with Parkinson's disease |
| Q55497257 | Integrated Analysis and Identification of Novel Biomarkers in Parkinson's Disease. |
| Q53074377 | Integration of risk factors for Parkinson disease in 2 large longitudinal cohorts. |
| Q48520930 | Interaction between caffeine and polymorphisms of glutamate ionotropic receptor NMDA type subunit 2A (GRIN2A) and cytochrome P450 1A2 (CYP1A2) on Parkinson's disease risk |
| Q47827804 | Intermittent Fasting Applied in Combination with Rotenone Treatment Exacerbates Dopamine Neurons Degeneration in Mice. |
| Q46352031 | Iron-induced generation of mitochondrial ROS depends on AMPK activity |
| Q58589932 | K-variant BCHE and pesticide exposure: Gene-environment interactions in a case-control study of Parkinson's disease in Egypt |
| Q55240777 | Linking Neuroinflammation and Neurodegeneration in Parkinson's Disease. |
| Q92423135 | Lipid and Lipid Raft Alteration in Aging and Neurodegenerative Diseases: A Window for the Development of New Biomarkers |
| Q57210882 | Metabolic syndrome and risk of Parkinson disease: A nationwide cohort study |
| Q92284964 | Metabolomics Analyses from Tissues in Parkinson's Disease |
| Q89796785 | MicroRNA-150 serves as a diagnostic biomarker and is involved in the inflammatory pathogenesis of Parkinson's disease |
| Q47102033 | MicroRNAs and Target Genes As Biomarkers for the Diagnosis of Early Onset of Parkinson Disease. |
| Q90745434 | Microbiota and Other Preventive Strategies and Non-genetic Risk Factors in Parkinson's Disease |
| Q99414195 | Milk and Fermented Milk Intake and Parkinson's Disease: Cohort Study |
| Q64078913 | More Research Is Needed on Lifestyle Behaviors That Influence Progression of Parkinson's Disease |
| Q91930166 | NEAT1 is overexpressed in Parkinson's disease substantia nigra and confers drug-inducible neuroprotection from oxidative stress |
| Q47098715 | Neurochemical and Behavior Deficits in Rats with Iron and Rotenone Co-treatment: Role of Redox Imbalance and Neuroprotection by Biochanin A. |
| Q89736107 | Neuropsychiatric Disorders in Parkinson's Disease: What Do We Know About the Role of Dopaminergic and Non-dopaminergic Systems? |
| Q64819927 | Neurotheranostics as personalized medicines |
| Q58573290 | Nicotine promotes neuron survival and partially protects from Parkinson's disease by suppressing SIRT6 |
| Q98281049 | No association between proton pump inhibitor use and ALS risk: a nationwide nested case-control study |
| Q38736768 | No clear support for a role for vitamin D in Parkinson's disease: A Mendelian randomization study |
| Q39229450 | Non-human primate models of PD to test novel therapies |
| Q58739806 | Nonsteroidal anti-inflammatory drugs use and risk of Parkinson disease: A dose-response meta-analysis |
| Q92641926 | Nutritional Risk Factors, Microbiota and Parkinson's Disease: What Is the Current Evidence? |
| Q59806685 | On the Use of -Distributed Stochastic Neighbor Embedding for Data Visualization and Classification of Individuals with Parkinson's Disease |
| Q47639323 | Oral Exposure to Paraquat Triggers Earlier Expression of Phosphorylated α-Synuclein in the Enteric Nervous System of A53T Mutant Human α-Synuclein Transgenic Mice |
| Q93192814 | Overall and Disease Related Mortality in Parkinson's Disease - a Longitudinal Cohort Study |
| Q93020146 | ParkProTrain: an individualized, tablet-based physiotherapy training programme aimed at improving quality of life and participation restrictions in PD patients - a study protocol for a quasi-randomized, longitudinal and sequential multi-method study |
| Q33619405 | Parkinson Disease: An Evolutionary Perspective |
| Q36319286 | Parkinson disease |
| Q90049837 | Parkinson's Disease: A Systemic Inflammatory Disease Accompanied by Bacterial Inflammagens |
| Q92593925 | Parkinson's disease in the Western Pacific Region |
| Q88766046 | Parkinson's disease increases the risk of perioperative complications after total knee arthroplasty: a nationwide database study |
| Q64779012 | Parkinsonism Relating to Intoxication with Glyphosate |
| Q59335760 | Patient-Derived Induced Pluripotent Stem Cells and Organoids for Modeling Alpha Synuclein Propagation in Parkinson's Disease |
| Q48117806 | Pharmacotherapy of Cardiovascular Autonomic Dysfunction in Parkinson Disease |
| Q111347824 | Phytochemicals and silk proteins in mature silkworm powders responsible for extended life expectancy and enhanced resistances to Parkinson's disease |
| Q58694525 | Pioglitazone use and Parkinson's disease: a retrospective cohort study in Taiwan |
| Q55488481 | Plin4-Dependent Lipid Droplets Hamper Neuronal Mitophagy in the MPTP/p-Induced Mouse Model of Parkinson's Disease. |
| Q94571881 | Poststroke Parkinsonism associates with an increased mortality risk in patients |
| Q89640236 | Posttraumatic parkinsonism would increase the mortality risk in elderly patients with traumatic brain injury |
| Q90181986 | Potential Roles of Exosomes in Parkinson's Disease: From Pathogenesis, Diagnosis, and Treatment to Prognosis |
| Q58486541 | Prevention of progression in Parkinson's disease |
| Q33843079 | Protein-Restricted Diets for Ameliorating Motor Fluctuations in Parkinson's Disease |
| Q57166759 | REM sleep behaviour disorder |
| Q64859345 | Raf kinase inhibitor protein protects microglial cells against 1-methyl-4-phenylpyridinium-induced neuroinflammation in vitro |
| Q48288262 | Regional analysis and genetic association of nigrostriatal degeneration in Lewy body disease |
| Q91936690 | Retinal correlates of neurological disorders |
| Q92150656 | Revealing Adenosine A2A-Dopamine D2 Receptor Heteromers in Parkinson's Disease Post-Mortem Brain through a New AlphaScreen-Based Assay |
| Q88968501 | Revisiting the Paraquat-Induced Sporadic Parkinson's Disease-Like Model |
| Q99564428 | Risk factors of Parkinson's disease: Simultaneous assessment, interactions and etiological subtypes |
| Q60921580 | Roco Proteins: GTPases with a Baroque Structure and Mechanism |
| Q61806045 | Role of Soluble Epoxide Hydrolase in Metabolism of PUFAs in Psychiatric and Neurological Disorders |
| Q97588584 | Sacral Nerve Stimulation in Parkinson's Disease Patients with Overactive Bladder Symptoms |
| Q94602327 | Self-Management Education for Persons with Parkinson's Disease and Their Care Partners: A Quasi-Experimental Case-Control Study in Clinical Practice |
| Q90394142 | Self-reported visual dysfunction in Parkinson disease: the Survey of Health, Ageing and Retirement in Europe |
| Q98735783 | Serum Calcium Levels and Parkinson's Disease: A Mendelian Randomization Study |
| Q90331718 | Seven facts and five initiatives for gut microbiome research |
| Q92407455 | Sex differences in movement disorders |
| Q47652448 | Sex differences in sleep apnea and comorbid neurodegenerative diseases. |
| Q58784650 | Sex: A Significant Risk Factor for Neurodevelopmental and Neurodegenerative Disorders |
| Q45201060 | Simvastatin as a Potential Disease-Modifying Therapy for Patients with Parkinson's Disease: Rationale for Clinical Trial, and Current Progress |
| Q91633928 | Sleep and risk of parkinsonism and Parkinson's disease: a population-based study |
| Q64768970 | Small molecule-driven NLRP3 inflammation inhibition via interplay between ubiquitination and autophagy: implications for Parkinson disease |
| Q64875477 | Soluble epoxide hydrolase plays a key role in the pathogenesis of Parkinson's disease |
| Q64865748 | Stroke and Coronary Artery Disease Are Associated With Parkinson's Disease |
| Q95840299 | Substantia nigra echogenicity is associated with serum ferritin, gender and iron-related genes in Parkinson's disease |
| Q55153472 | Tai Chi for Reducing Dual-task Gait Variability, a Potential Mediator of Fall Risk in Parkinson's Disease: A Pilot Randomized Controlled Trial. |
| Q59830619 | Targeting Metalloenzymes for Therapeutic Intervention |
| Q47662113 | The Changing Landscape of Parkinson Epidemiologic Research |
| Q90637954 | The Effect of Estrogen Replacement Therapy on Alzheimer's Disease and Parkinson's Disease in Postmenopausal Women: A Meta-Analysis |
| Q64769017 | The Emerging Role of Biomarkers in Adaptive Modulation of Clinical Brain Stimulation |
| Q90597572 | The PERK-Dependent Molecular Mechanisms as a Novel Therapeutic Target for Neurodegenerative Diseases |
| Q58726908 | The Role of TMEM230 Gene in Parkinson's Disease |
| Q60950155 | The Search for Environmental Causes of Parkinson's Disease: Moving Forward |
| Q90722250 | The Study of Subthalamic Deep Brain Stimulation for Parkinson Disease-Associated Camptocormia |
| Q57051340 | The Synergy of Aging and LPS Exposure in a Mouse Model of Parkinson's Disease |
| Q64785248 | The association between lifestyle factors and Parkinson's disease progression and mortality |
| Q92713972 | The interplay of aging, genetics and environmental factors in the pathogenesis of Parkinson's disease |
| Q47146624 | The neuroprotective effect of nicotine in Parkinson's disease models is associated with inhibiting PARP-1 and caspase-3 cleavage |
| Q89754247 | The relationship between Parkinson's disease symptoms and caregiver quality of life |
| Q99635876 | The relationships of vitamin D, vitamin D receptor gene polymorphisms, and vitamin D supplementation with Parkinson's disease |
| Q91246297 | Time Trends of the Incidence, Prevalence, and Mortality of Parkinsonism |
| Q97652836 | Tinnitus and risk of Alzheimer's and Parkinson's disease: a retrospective nationwide population-based cohort study |
| Q58697812 | Triglyceride Form of Docosahexaenoic Acid Mediates Neuroprotection in Experimental Parkinsonism |
| Q54980572 | Tubulin and Tau: Possible targets for diagnosis of Parkinson's and Alzheimer's diseases. |
| Q48050909 | Two mTOR inhibitors, rapamycin and Torin 1, differentially regulate iron-induced generation of mitochondrial ROS. |
| Q48092663 | Understanding Miro GTPases: Implications in the Treatment of Neurodegenerative Disorders. |
| Q99585428 | Using Mendelian randomization to understand and develop treatments for neurodegenerative disease |
| Q90671795 | What and How Can Physical Activity Prevention Function on Parkinson's Disease? |
| Q51763128 | When nature's robots go rogue: exploring protein homeostasis dysfunction and the implications for understanding human aging disease pathologies. |
| Q92863735 | mHealth and wearable technology should replace motor diaries to track motor fluctuations in Parkinson's disease |
| Q91105867 | α-Synuclein oligomers mediate the aberrant form of spike-induced calcium release from IP3 receptor |
| Q93063055 | β-adrenoreceptors and the risk of Parkinson's disease |
Search more.